Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
Morris, Gerwyn, Maes, Michael, Berk, Michael et al. · Metabolic brain disease · 2019 · DOI
Quick Summary
This study proposes a theory for how ME/CFS might develop, starting with an infection that triggers lasting problems in the body's immune system and stress response. The authors suggest that in genetically vulnerable people, this leads to a chain of events: increased inflammation, intestinal problems that allow bacteria-related substances to enter the bloodstream, nervous system dysfunction, and eventually a state where the immune system becomes exhausted and less able to fight back. This model tries to explain why ME/CFS patients have the specific symptoms and lab abnormalities doctors observe.
Why It Matters
Understanding how ME/CFS develops is essential for identifying potential treatment targets and biomarkers. This comprehensive mechanistic model connects multiple known abnormalities in ME/CFS patients into a coherent biological narrative, providing a testable framework that could guide future research into prevention and therapeutic interventions. For patients, a validated disease mechanism could improve medical recognition and lead to more effective treatments.
Observed Findings
Literature indicates ME/CFS patients show chronic inflammatory and oxidative stress markers
Evidence documents neuroinflammation and neurocognitive abnormalities in ME/CFS cohorts
Studies have identified dysautonomia and mitochondrial performance impairment in patient populations
Research demonstrates markers of immune regulation including altered T cell and macrophage function
Increased intestinal permeability has been reported in some ME/CFS patients
Inferred Conclusions
Post-infection triggering of DAMPs in genetically predisposed individuals initiates a cascade of chronic inflammation and oxidative stress that characterizes ME/CFS
Immune exhaustion and metabolic downregulation via endotoxin tolerance mechanisms can explain the sustained symptom profile and immune abnormalities observed in ME/CFS
Dysautonomia, neuroinflammation, and mitochondrial dysfunction are interconnected consequences of chronic immune activation and stress rather than independent pathologies
Remaining Questions
Which specific genetic factors confer susceptibility to chronic post-infection immune dysregulation in ME/CFS?
What precipitating infections or infection characteristics most reliably trigger this disease pathway?
What This Study Does Not Prove
This is a theoretical model based on integrating existing literature rather than new experimental data, so it does not definitively prove the proposed sequence of events occurs in ME/CFS patients. The model does not establish causation for individual mechanisms and cannot prove that endotoxin tolerance is the primary driver of ME/CFS rather than a secondary consequence. Validation would require prospective clinical studies tracking patients at each proposed disease stage.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Can endotoxin tolerance be reversed therapeutically, and would reversal restore normal immune and metabolic function?
How do individual ME/CFS patients vary in which mechanism (neuroinflammation, mitochondrial dysfunction, dysautonomia) predominates, and does this variation predict treatment response?